dehydroepiandrosterone and Disease Models, Animal studies

Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

Excerpt	Relevance	Reference
"Although nerolidol (NRL) is a naturally occurring sesquiterpene alcohol with many pharmacological activities, its role in dehydroepiandrosterone DHEA-induced polycystic ovary syndrome PCOS is unknown."	8.31	Nerolidol attenuates dehydroepiandrosterone-induced polycystic ovary syndrome in rats by regulating oxidative stress and decreasing apoptosis. ( Aydın, M; Çiftçi, O; Doğan, A; Hayal, TB; Özek, DA; Taşlıdere, A; Türkmen, NB; Ünüvar, S; Yaşar, Ş; Yüce, H, 2023)
"Female Sprague Dawley (SD) rats were treated with Dehydroepiandrosterone (DHEA) (6 mg/100g) opting the post-pubertal approach for developing rat model of polycystic ovarian syndrome, Metformin was used as standard."	8.12	Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis. ( Hu, Y; Peng, F; Peng, S; Shi, L; Zeng, N, 2022)
"Almost every female classic galactosemia patient develops primary ovarian insufficiency (POI)."	7.91	Dehydroepiandrosterone supplementation attenuates ovarian ageing in a galactose-induced primary ovarian insufficiency rat model. ( Akouri, R; Demir, N; Erman, M; Gunduz, T; Ozekinci, M; Sozen, B, 2019)
" Here, we found that 3 weeks of rutin (a novel compound for BAT activation) treatment increased BAT activation, thereby it improved thermogenesis and systemic insulin sensitivity in dehydroepiandrosterone (DHEA)-induced PCOS rat."	7.85	Brown adipose tissue activation by rutin ameliorates polycystic ovary syndrome in rat. ( Dong, M; Hu, T; Huang, Y; Jin, W; Lee, HJ; Lim, W; Lin, J; Liu, Q; Wei, G; Ye, R; Yuan, X; Zhang, C; Zhang, H; Zhou, H, 2017)
"To investigate the expression of silent information regulator 1 (SIRT1) in rats with polycystic ovary syndrome (PCOS) and its alteration after exenatide treatment."	7.81	Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. ( Ge, SQ; Tao, X; Zhang, B; Zhang, EH; Zhang, X, 2015)
"Recently the benefit of subcutaneously applied dehydroepiandrosterone (DHEA) during sepsis was demonstrated."	7.80	Androstenediol modulates sepsis induced alterations of survival and immune functions in a murine model of sepsis. ( Lendemans, S; Oberbeck, R; Schmitz, D, 2014)
"To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia."	7.80	Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice. ( Kilic, FS; Kulluk, D; Musmul, A, 2014)
"Dehydroepiandrosterone (DHEA) was shown to improve the immune function and survival in experimental sepsis."	7.80	Combination of dehydroepiandrosterone and orthovanadate administration reduces intestinal leukocyte recruitment in models of experimental sepsis. ( Al-Banna, N; Bac, VH; Balzer, C; Jaskulski, M; Lehmann, C; Nedeljkov, V; Pavlovic, D; Sharawi, N; Weber, S, 2014)
"Dehydroepiandrosterone (DHEA) prevents chronic hypoxia-induced pulmonary hypertension and associated right ventricle dysfunction in rats."	7.78	Dehydroepiandrosterone reverses chronic hypoxia/reoxygenation-induced right ventricular dysfunction in rats. ( Amor-Carro, Ó; Begueret, H; Bellance, N; Billaud, M; Dahan, D; dos Santos, P; Ducret, T; Dumas de La Roque, E; Fayon, M; Marthan, R; Ramos-Barbón, D; Rossignol, R; Savineau, JP, 2012)
"Administration of dehydroepiandrosterone (DHEA) has been demonstrated to improve survival and cellular immune functions during systemic inflammation."	7.76	Dehydroepiandrosterone modulates survival and immune functions during sepsis depending on the way of drug administration. ( Hammes, F; Kobbe, P; Oberbeck, R; Schmitz, D; Wegner, A, 2010)
"The purpose of this study was to examine the effect of DHEA (Dehydroepiandrosterone) on muscle weight and Type I and II fiber cross-sectional area of affected and unaffected hindlimb muscles in rats with neuropathic pain induced by unilateral peripheral nerve injury."	7.75	[Effect of dehydroepiandrosterone on affected and unaffected hindlimb muscles in rats with neuropathic pain induced by unilateral peripheral nerve injury]. ( An, GJ; Choe, MA, 2009)
"Dehydroepiandrosterone (DHEA) treatment provides diverse anti-inflammatory benefits in rodent models of diseases, including rheumatoid arthritis (RA), but only limited benefits to patients."	7.75	An orally bioavailable synthetic analog of an active dehydroepiandrosterone metabolite reduces established disease in rodent models of rheumatoid arthritis. ( Auci, DL; Boyle, DL; Firestein, GS; Frincke, JM; Garsd, A; Offner, H; Pieters, R; Reading, CL; White, SK, 2009)
"The aim of this study was to investigate the effects of intra-articular injection of dehydroepiandrosterone (DHEA) on cartilage and synovium of knee joints with osteoarthritis (OA) in rabbits and the underlying mechanism."	7.73	Effect of dehydroepiandrosterone on cartilage and synovium of knee joints with osteoarthritis in rabbits. ( Feng, J; Wu, LD; Xiong, Y; Yu, HC, 2006)
"The effect of castration and subsequent replacement of dehydroepiandrosterone (DHEA) or estradiol on parasitemia, mortality and incidence of cerebral malaria (CM) was evaluated in CBA mice infected with Plasmodium berghei ANKA."	7.73	Estradiol, but not dehydroepiandrosterone, decreases parasitemia and increases the incidence of cerebral malaria and the mortality in plasmodium berghei ANKA-infected CBA mice. ( Carvalho, LJ; Cunha, MG; Daniel-Ribeiro, CT; do Nascimento, JL; Libonati, RM; Oliveira, SG; Santos, MV; Souza, JM, 2006)
"Progressive ischemia and necrosis of the skin following thermal injury are reduced by postburn administration of the steroid hormone dehydroepiandrosterone (DHEA)."	7.69	Dehydroepiandrosterone reduces progressive dermal ischemia caused by thermal injury. ( Araneo, BA; Barton, S; Daynes, RA; Ryu, SY, 1995)
"The mice in Continue dosing groups maintained reproductive phenotypes of PCOS mouse models."	5.91	Dehydroepiandrosterone-induced polycystic ovary syndrome mouse model requires continous treatments to maintain reproductive phenotypes. ( Kang, J; Wu, H; Yao, Q; Zhao, B, 2023)
"Treatment with quercetin increased the adiponectin level and expression of adipoR1 and nesfatin-1 and decreased both the expression of aromatase and the oestradiol level."	5.56	The phytoestrogen, quercetin, in serum, uterus and ovary as a potential treatment for dehydroepiandrosterone-induced polycystic ovary syndrome in the rat. ( Jafari Khorchani, M; Neisy, A; Zal, F, 2020)
"Inflammation is likely to be a crucial contributor to the pathogenesis of PCOS."	5.51	Dehydroepiandrosterone stimulates inflammation and impairs ovarian functions of polycystic ovary syndrome. ( Bulbul, A; Chen, S; Cui, X; Li, Y; Liu, S; Sun, D; Yan, Q; Zheng, Q, 2019)
"Hyperandrogenism is the hallmark of polycystic ovary syndrome (PCOS)."	5.48	The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome. ( Ho, LT; Huang, SW; Juan, CC; Seow, KM; Ting, CH, 2018)
"These findings suggest that DHEA treatment induced depression-like behavior in PCOS mice, possibly through down-regulation of brain monoamines and/or their metabolites, which implies the contribution of hyperandrogenism to the psychological symptoms of women with PCOS."	5.43	Depression-Like Behavior in a Dehydroepiandrosterone-Induced Mouse Model of Polycystic Ovary Syndrome. ( Hao, S; Kang, J; Shen, Q; Song, X; Wang, H; Yu, Q, 2016)
"DHEA treatment did not alter disease progression or survival in SOD1-G93A rats."	5.38	Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis. ( Hayes-Punzo, A; McHugh, J; Meyer, M; Mulcrone, P; Suzuki, M; Svendsen, CN, 2012)
"Sepsis is associated with a marked depression of cellular immune function."	5.31	Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. ( Dahlweid, M; Emmendörfer, A; Koch, R; Oberbeck, R; Pape, HC; Tscherne, H; van Griensven, M, 2001)
"Forebrain ischemia was induced for 10 min using a modified four-vessel occlusion technique, with hippocampal neuronal injury assessed at 7 days post-ischemically and expressed as a percentage of total cells."	5.31	Dehydroepiandrosterone (DHEA) reduces neuronal injury in a rat model of global cerebral ischemia. ( Buchan, AM; Klein, G; Li, H; Sun, P, 2001)
" Observational studies do not support the hypothesis that dehydroepiandrosterone sulfate deficiency is a risk factor for coronary artery disease."	4.82	Androgens and coronary artery disease. ( von Eckardstein, A; Wu, FC, 2003)
"Although nerolidol (NRL) is a naturally occurring sesquiterpene alcohol with many pharmacological activities, its role in dehydroepiandrosterone DHEA-induced polycystic ovary syndrome PCOS is unknown."	4.31	Nerolidol attenuates dehydroepiandrosterone-induced polycystic ovary syndrome in rats by regulating oxidative stress and decreasing apoptosis. ( Aydın, M; Çiftçi, O; Doğan, A; Hayal, TB; Özek, DA; Taşlıdere, A; Türkmen, NB; Ünüvar, S; Yaşar, Ş; Yüce, H, 2023)
" To that end, we have established a Swiss albino mouse model of PCOS based on 3 weeks of daily treatment with letrozole (50 μg/day; intraperitoneal) and dehydroepiandrosterone (DHEA, 6 mg/100 g body weight; subcutaneous) in 5-week-old female mice fed on normal or high-fat diet (HFD)."	4.12	Distinctions in PCOS Induced by Letrozole Vs Dehydroepiandrosterone With High-fat Diet in Mouse Model. ( Adiga, SK; Bakkum-Gamez, J; Chang, AY; DeStephano, C; Kalthur, G; Kalthur, SG; Kannan, N; Kundapur, SD; Mutalik, S; Nayak, G; Panchanan, G; Poojary, PS; Rao, A; Sherman, M; Zhao, Y, 2022)
"Female Sprague Dawley (SD) rats were treated with Dehydroepiandrosterone (DHEA) (6 mg/100g) opting the post-pubertal approach for developing rat model of polycystic ovarian syndrome, Metformin was used as standard."	4.12	Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis. ( Hu, Y; Peng, F; Peng, S; Shi, L; Zeng, N, 2022)
"Hyponatremia due to elevated arginine vasopressin (AVP) secretion increases mortality in liver failure patients."	4.02	Sex Differences in the Regulation of Vasopressin and Oxytocin Secretion in Bile Duct-Ligated Rats. ( Bachelor, ME; Balapattabi, K; Cunningham, JT; Cunningham, RL; Little, JT, 2021)
"Female prepubertal rats were treated with equine chorionic gonadotropin (eCG) to induce folliculogenesis, together with dehydroepiandrosterone (DHEA) to induce hyperandrogenism and/or PGZ to evaluate PPARG activation."	3.91	Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats. ( Abruzzese, GA; Ferreira, SR; Heber, MF; Motta, AB; Velez, LM, 2019)
"Almost every female classic galactosemia patient develops primary ovarian insufficiency (POI)."	3.91	Dehydroepiandrosterone supplementation attenuates ovarian ageing in a galactose-induced primary ovarian insufficiency rat model. ( Akouri, R; Demir, N; Erman, M; Gunduz, T; Ozekinci, M; Sozen, B, 2019)
" The following study investigates the ovarian hyperfibrosis forming via transforming growth factor-β (TGF-β) signaling pathway in Dehydroepiandrosterone (DHEA)- induced polycystic ovary syndrome (PCOS) rat model."	3.88	DHEA-induced ovarian hyperfibrosis is mediated by TGF-β signaling pathway. ( Gao, Q; He, X; Liang, Q; Shen, S; Wang, D; Wang, H; Wang, W; Wang, Y; Xia, Y, 2018)
" Employing polymerase chain reaction and flow cytometry, we analyzed the transcript and expression levels of downstream molecules of RHOG, DOCK1, and RAC1 in the polycystic ovarian syndrome (PCOS) ovary along with normal antral follicular theca and granulosa cells after dehydroepiandrosterone (DHEA) supplementation."	3.85	RHOG-DOCK1-RAC1 Signaling Axis Is Perturbed in DHEA-Induced Polycystic Ovary in Rat Model. ( Chadchan, S; Chaturvedi, H; Dwivedi, A; Jha, RK; Kumar, V; Maurya, R; Maurya, VK; Singh, R; Soni, UK; Ubba, V, 2017)
" Here, we found that 3 weeks of rutin (a novel compound for BAT activation) treatment increased BAT activation, thereby it improved thermogenesis and systemic insulin sensitivity in dehydroepiandrosterone (DHEA)-induced PCOS rat."	3.85	Brown adipose tissue activation by rutin ameliorates polycystic ovary syndrome in rat. ( Dong, M; Hu, T; Huang, Y; Jin, W; Lee, HJ; Lim, W; Lin, J; Liu, Q; Wei, G; Ye, R; Yuan, X; Zhang, C; Zhang, H; Zhou, H, 2017)
"0 g/kg/day, per os) on endometrial abnormalities in a dehydroepiandrosterone (DHEA, subcutaneous)-induced polycystic ovary syndrome (PCOS) rat model."	3.83	Effects of Oriental Medicine Kyung-Ok-Ko on Uterine Abnormality in Hyperandrogenized Rats. ( Bae, CS; Cho, IH; Jang, M; Kim, HJ; Kim, YO; Lee, MJ; Lee, S; Lee, SW; Park, KS, 2016)
"To investigate the expression of silent information regulator 1 (SIRT1) in rats with polycystic ovary syndrome (PCOS) and its alteration after exenatide treatment."	3.81	Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. ( Ge, SQ; Tao, X; Zhang, B; Zhang, EH; Zhang, X, 2015)
"The objective of this study was to investigate the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) in adipose tissue of the rat model of polycystic ovary syndrome (PCOS), induced by dehydroepiandrosterone (DHEA)."	3.80	Expression of PPAR-γ in adipose tissue of rats with polycystic ovary syndrome induced by DHEA. ( Wang, YX; Xie, BG; Zhu, WJ, 2014)
"To investigate the protective effect of DHEA on indomethacin-induced gastric ulcers in rats."	3.80	The impact of dehydroepiandrosterone on indomethacin-induced gastric lesions in rats. ( Alessa, R; Alkhateeb, M; Bayoumy, NM; Bin-Jaliah, I; Eleawa, S; Sakr, HF, 2014)
"To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia."	3.80	Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice. ( Kilic, FS; Kulluk, D; Musmul, A, 2014)
"Dehydroepiandrosterone (DHEA) was shown to improve the immune function and survival in experimental sepsis."	3.80	Combination of dehydroepiandrosterone and orthovanadate administration reduces intestinal leukocyte recruitment in models of experimental sepsis. ( Al-Banna, N; Bac, VH; Balzer, C; Jaskulski, M; Lehmann, C; Nedeljkov, V; Pavlovic, D; Sharawi, N; Weber, S, 2014)
"Recently the benefit of subcutaneously applied dehydroepiandrosterone (DHEA) during sepsis was demonstrated."	3.80	Androstenediol modulates sepsis induced alterations of survival and immune functions in a murine model of sepsis. ( Lendemans, S; Oberbeck, R; Schmitz, D, 2014)
"Dehydroepiandrosterone (DHEA) prevents chronic hypoxia-induced pulmonary hypertension and associated right ventricle dysfunction in rats."	3.78	Dehydroepiandrosterone reverses chronic hypoxia/reoxygenation-induced right ventricular dysfunction in rats. ( Amor-Carro, Ó; Begueret, H; Bellance, N; Billaud, M; Dahan, D; dos Santos, P; Ducret, T; Dumas de La Roque, E; Fayon, M; Marthan, R; Ramos-Barbón, D; Rossignol, R; Savineau, JP, 2012)
" The purpose of this study was to investigate the motor function, anxiety levels, depression-related emotional responses, attentional function and plasma levels of testosterone and dehydroepiandrosterone (DHEA) in SAMP10."	3.76	Depression-like behavior and reduced plasma testosterone levels in the senescence-accelerated mouse. ( Egashira, N; Fujiwara, M; Iwasaki, K; Koushi, E; Mishima, K; Oishi, R; Okuno, R; Shirakawa, A, 2010)
"Administration of dehydroepiandrosterone (DHEA) has been demonstrated to improve survival and cellular immune functions during systemic inflammation."	3.76	Dehydroepiandrosterone modulates survival and immune functions during sepsis depending on the way of drug administration. ( Hammes, F; Kobbe, P; Oberbeck, R; Schmitz, D; Wegner, A, 2010)
"Dehydroepiandrosterone (DHEA) improves survival after trauma and sepsis, while mechanisms of action are not yet fully understood."	3.75	DHEA-dependent and organ-specific regulation of TNF-alpha mRNA expression in a murine polymicrobial sepsis and trauma model. ( Barkhausen, T; Hildebrand, F; Krettek, C; van Griensven, M, 2009)
"Dehydroepiandrosterone (DHEA) treatment provides diverse anti-inflammatory benefits in rodent models of diseases, including rheumatoid arthritis (RA), but only limited benefits to patients."	3.75	An orally bioavailable synthetic analog of an active dehydroepiandrosterone metabolite reduces established disease in rodent models of rheumatoid arthritis. ( Auci, DL; Boyle, DL; Firestein, GS; Frincke, JM; Garsd, A; Offner, H; Pieters, R; Reading, CL; White, SK, 2009)
"The purpose of this study was to examine the effect of DHEA (Dehydroepiandrosterone) on muscle weight and Type I and II fiber cross-sectional area of affected and unaffected hindlimb muscles in rats with neuropathic pain induced by unilateral peripheral nerve injury."	3.75	[Effect of dehydroepiandrosterone on affected and unaffected hindlimb muscles in rats with neuropathic pain induced by unilateral peripheral nerve injury]. ( An, GJ; Choe, MA, 2009)
"The aim of this study was to investigate the effects of intra-articular injection of dehydroepiandrosterone (DHEA) on cartilage and synovium of knee joints with osteoarthritis (OA) in rabbits and the underlying mechanism."	3.73	Effect of dehydroepiandrosterone on cartilage and synovium of knee joints with osteoarthritis in rabbits. ( Feng, J; Wu, LD; Xiong, Y; Yu, HC, 2006)
"The effect of castration and subsequent replacement of dehydroepiandrosterone (DHEA) or estradiol on parasitemia, mortality and incidence of cerebral malaria (CM) was evaluated in CBA mice infected with Plasmodium berghei ANKA."	3.73	Estradiol, but not dehydroepiandrosterone, decreases parasitemia and increases the incidence of cerebral malaria and the mortality in plasmodium berghei ANKA-infected CBA mice. ( Carvalho, LJ; Cunha, MG; Daniel-Ribeiro, CT; do Nascimento, JL; Libonati, RM; Oliveira, SG; Santos, MV; Souza, JM, 2006)
"To investigate the effects of dehydroepiandrosterone (DHEA) on Ca(2+)-activated K(+) (K(Ca)) channel and mean pulmonary arterial pressure (mPAP) in rats with chronic pulmonary hypertension."	3.72	[Effect of dehydroepiandrosterone on Ca(2+)-activated K+ channel of pulmonary arterial smooth muscle cells in pulmonary hypertensive rats]. ( Chen, WB; Chen, Z; Cheng, DY; Xiao, XR, 2004)
"Dehydroepiandrosterone (DHEA) exerts a variety of positive effects on the immunologic alterations after trauma and sepsis."	3.71	Dehydroepiandrosterone (DHEA) modulates the activity and the expression of lymphocyte subpopulations induced by cecal ligation and puncture. ( Böttcher, F; Breddin, M; Dahlweid, FM; Giannoudis, PV; Pape, HC; van Griensven, M; Wittwer, T, 2002)
"Using croton oil-induced ear edema model and applying confocal laser scanning microscopy, flow cytometry, immuno-fluorescent techniques to investigate the inhibitory effect of DHEA on tumor promotion."	3.71	[Studies on the anti-tumorpromotion activities of dehydroepiandrosterone and its mechanism of action]. ( Fu, ZD; Han, R; Yang, S, 2001)
"To investigate whether dehydroepiandrosterone (DHEA), an adrenal/gonadal androgen, can act centrally to reduce energy intake in a model of genetic obesity, the Zucker fatty rat."	3.69	Central effects of dehydroepiandrosterone in Zucker rats. ( Porter, JR; Svec, F; Wright, BE, 1995)
"Dehydroepiandrosterone (DHEA) decreases body weight and food intake of the obese Zucker rat, a model of youth-onset obesity associated with hyperphagia."	3.69	The effect of discontinuing dehydroepiandrosterone supplementation on Zucker rat food intake and hypothalamic neurotransmitters. ( Abadie, JM; Browne, ES; Porter, JR; Svec, F; Wright, BE, 1995)
"Progressive ischemia and necrosis of the skin following thermal injury are reduced by postburn administration of the steroid hormone dehydroepiandrosterone (DHEA)."	3.69	Dehydroepiandrosterone reduces progressive dermal ischemia caused by thermal injury. ( Araneo, BA; Barton, S; Daynes, RA; Ryu, SY, 1995)
"Aldose reductase catalyzes the NADPH-linked reduction of hexoses to their respective sugar-alcohols, which are involved in the pathogenesis of "sugar-cataracts"."	3.68	Effects of G-6-PD deficiency, experimentally induced or genetically transmitted, on the sorbitol pathway activity. In vitro and in vivo studies. ( Alvarez, A; Chávez, M; Chávez-Anaya, E; Medina, C; Medina, MD; Mendoza, R; Ramírez, MG; Sáenz, G; Vaca, G; Vargas, M, 1992)
"Over 80% of Addison's disease is of the autoimmune type, though almost any systemic destructive process can cause similar steroid insufficiency."	2.37	Adrenocortical insufficiency. ( Burke, CW, 1985)
"The mice in Continue dosing groups maintained reproductive phenotypes of PCOS mouse models."	1.91	Dehydroepiandrosterone-induced polycystic ovary syndrome mouse model requires continous treatments to maintain reproductive phenotypes. ( Kang, J; Wu, H; Yao, Q; Zhao, B, 2023)
"Nonalcoholic fatty liver disease (NAFLD) is the leading liver chronic disease featuring hepatic steatosis."	1.62	The Mitochondrial Trigger in an Animal Model of Nonalcoholic Fatty Liver Disease. ( Aimaretti, E; Aragno, M; Chimienti, G; D'Attoma, B; Lezza, AMS; Orlando, A; Pesce, V; Russo, F, 2021)
"Type 2 diabetes is clinically associated with progressive necroinflammation and fibrosis in nonalcoholic steatohepatitis (NASH)."	1.56	AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes. ( Ali, M; Charville, GW; Das, S; Dehnad, A; Fan, W; Fish, SR; Jiang, JX; Li, Y; Mozes, G; Olson, KA; Török, NJ; Wong, KA, 2020)
"Treatment with quercetin increased the adiponectin level and expression of adipoR1 and nesfatin-1 and decreased both the expression of aromatase and the oestradiol level."	1.56	The phytoestrogen, quercetin, in serum, uterus and ovary as a potential treatment for dehydroepiandrosterone-induced polycystic ovary syndrome in the rat. ( Jafari Khorchani, M; Neisy, A; Zal, F, 2020)
"Inflammation is likely to be a crucial contributor to the pathogenesis of PCOS."	1.51	Dehydroepiandrosterone stimulates inflammation and impairs ovarian functions of polycystic ovary syndrome. ( Bulbul, A; Chen, S; Cui, X; Li, Y; Liu, S; Sun, D; Yan, Q; Zheng, Q, 2019)
"Hyperandrogenism is the hallmark of polycystic ovary syndrome (PCOS)."	1.48	The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome. ( Ho, LT; Huang, SW; Juan, CC; Seow, KM; Ting, CH, 2018)
"Metformin and combined treatment groups reduced the body and ovary weights compared to the PCOS group."	1.48	Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. ( Ceylan, S; Eraldemır, C; Furat Rencber, S; Guzel, E; Kum, T; Kurnaz Ozbek, S; Sezer, Z, 2018)
"Most patients with polycystic ovary syndrome have hyperandrogenism, caused by excess androgen synthesis."	1.46	The BMP4-Smad signaling pathway regulates hyperandrogenism development in a female mouse model. ( Ding, M; Dou, X; Du, SY; Liu, Y; Qian, SW; Tang, QQ; Wu, ZY; Xu, CJ; Zhang, FF; Zhang, W, 2017)
"These findings suggest that DHEA treatment induced depression-like behavior in PCOS mice, possibly through down-regulation of brain monoamines and/or their metabolites, which implies the contribution of hyperandrogenism to the psychological symptoms of women with PCOS."	1.43	Depression-Like Behavior in a Dehydroepiandrosterone-Induced Mouse Model of Polycystic Ovary Syndrome. ( Hao, S; Kang, J; Shen, Q; Song, X; Wang, H; Yu, Q, 2016)
"Kidney cancer is the sixth most common cancer in the United States, and its incidence is increasing."	1.43	Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy. ( Hammock, BD; Kim, J; Ulu, A; Wan, D; Weiss, RH; Yang, J, 2016)
"Dehydroepiandrosterone (DHEA) has been shown to have immunomodulatory effects after hemorrhage and sepsis."	1.40	Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model. ( Ewers, P; Hildebrand, F; Kobbe, P; Lichte, P; Pape, HC; Pfeifer, R; Pufe, T; Tohidnezhad, M; Werner, BE, 2014)
"Experimental autoimmune encephalomyelitis was induced in C57/BL6 mice."	1.40	HE3286 reduces axonal loss and preserves retinal ganglion cell function in experimental optic neuritis. ( Ahlem, C; Dine, K; Khan, RS; Luna, E; Shindler, KS, 2014)
"Breast cancer is the most frequently diagnosed cancer in women in the United States."	1.40	The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model. ( Arumugam, A; Lakshmanaswamy, R; Lissner, EA, 2014)
"Cardiac hypertrophy is associated with a switch towards increased glucose metabolism and decreased fatty acid metabolism."	1.39	Cardiac-specific hexokinase 2 overexpression attenuates hypertrophy by increasing pentose phosphate pathway flux. ( Baines, CP; Douglas, DL; Krenz, M; McCommis, KS, 2013)
"DHEA treatment did not alter disease progression or survival in SOD1-G93A rats."	1.38	Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis. ( Hayes-Punzo, A; McHugh, J; Meyer, M; Mulcrone, P; Suzuki, M; Svendsen, CN, 2012)
"These results suggest that memory deficits in AD may be improved by sominone independently of reducing amyloid plaques and neuroinflammation."	1.37	Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice, 5XFAD. ( Joyashiki, E; Matsuya, Y; Tohda, C, 2011)
"Alzheimer's disease was produced in young female ovariectomized rats by intraperitoneal administration of AlCl(3) (4."	1.37	Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer's disease. ( Ahmed, HH; Aly, HF; Metwally, FM, 2011)
"Dehydroepiandrosterone (DHEA) is a steroid hormone shown to reverse vascular remodeling in systemic vessels."	1.37	Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. ( Bisserier, M; Bonnet, S; Courboulin, A; Jacob, MH; Meloche, J; Paulin, R, 2011)
"Dehydroepiandrosterone (DHEA) is a naturally occurring adrenal androgen that has antioxidant properties."	1.37	The effect of DHEA treatment on the oxidative stress and myocardial fibrosis induced by Keshan disease pathogenic factors. ( Chen, X; Fan, Z; Jia, C; Li, M; Li, X; Miao, C; Ren, L; Sun, B, 2011)
"Perfluorooctanoic acid (PFOA) is a potent hepatocarcinogen and peroxisome proliferator (PP) in rodents."	1.35	Genomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout. ( Benninghoff, AD; Carpenter, HM; Hendricks, JD; Orner, GA; Pereira, CB; Tilton, SC; Williams, DE, 2008)
"Dehydroepiandrosterone (DHEA) is an abundant adrenal steroid in serum of humans, and has been reported to have anti-inflammatory, anti-proliferative, and certain immune-regulating properties."	1.35	Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats. ( Dou, YC; Duan, RS; Shi, CW; Sun, RP; Tan, XD, 2009)
"Dehydroepiandrosterone (DHEA) is a naturally occurring and clinically used steroid known to inhibit the Akt axis in cancer."	1.35	Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. ( Bonnet, S; Dromparis, P; Dyck, JR; Haromy, A; Michelakis, ED; Nagendran, J; Paulin, R; Roy, M; Sutendra, G; Watson, KO, 2009)
"Dehydroepiandrosterone (DHEA) is a weak androgen that exerts pleomorphic effects on the immune system."	1.35	Dehydroepiandrosterone in systemic lupus erythematosus. ( Kovats, S; Sawalha, AH, 2008)
"Hemorrhagic shock was produced in 20- to 30-kg male Yorkshire pigs anesthetized with 2% isoflurane by withdrawing blood through a carotid cannula to a mean arterial pressure (MAP) of 40 to 45 mm Hg and maintaining that level for 60 minutes by further removals of blood."	1.33	Effect of DHEA on the hemodynamic response to resuscitation in a porcine model of hemorrhagic shock. ( Chang, B; Helling, T; Morrison, DC; Nguyen, C; Steppacher, R; Tibbs, BM; Van Way, CW; Woodall, C; Yang, R, 2006)
"and aims: Primary sclerosing cholangitis is a Th1 cytokine driven disease with a poor clinical responsiveness to glucocorticoid therapy."	1.32	Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis. ( Le, T; Swain, MG; Tjandra, K, 2003)
"Forebrain ischemia was induced for 10 min using a modified four-vessel occlusion technique, with hippocampal neuronal injury assessed at 7 days post-ischemically and expressed as a percentage of total cells."	1.31	Dehydroepiandrosterone (DHEA) reduces neuronal injury in a rat model of global cerebral ischemia. ( Buchan, AM; Klein, G; Li, H; Sun, P, 2001)
" In vitro, all compounds demonstrated growth inhibition at a dose-response manner; however, manumycin, gliotoxin, and DHEA demonstrated an initial increase in growth rate at lower doses."	1.31	Chemopreventive efficacy of promising farnesyltransferase inhibitors. ( Crist, KA; Hara, M; Lantry, LE; Lubet, RA; Wang, Y; You, M; Zeeck, A; Zhang, Z, 2000)
" However, a dose-response reduction in invasive carcinoma growth was observed for both DFMO, an inhibitor of ornithine decarboxylase, and DHEA, the primary steroid precursor to both androgens and estrogens in primates."	1.31	2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. ( Anver, MR; Green, JE; Kelloff, G; Lubet, R; Moon, RC; Shibata, E; Shibata, MA, 2001)
"Other childhood seizures are also responsive to ACTH."	1.31	The effects of ACTH and adrenocorticosteroids on seizure susceptibility in 15-day-old male rats. ( Burnham, WM; Edwards, HE; Vimal, S, 2002)
"Sepsis is associated with a marked depression of cellular immune function."	1.31	Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. ( Dahlweid, M; Emmendörfer, A; Koch, R; Oberbeck, R; Pape, HC; Tscherne, H; van Griensven, M, 2001)
" DHEA inhibits prostate cancer induction both when chronic administration is begun prior to carcinogen exposure, and when administration is delayed until preneoplastic prostate lesions are present."	1.30	Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat. ( McCormick, DL; Rao, KV, 1999)

Research

Studies (178)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Endothelial Progenitor Cells

Timeframe	Studies, this research(%)	All Research%
pre-1990	10 (5.62)	18.7374
1990's	12 (6.74)	18.2507
2000's	44 (24.72)	29.6817
2010's	81 (45.51)	24.3611
2020's	31 (17.42)	2.80

Authors	Studies
Yang, YX	1
Zheng, LT	1
Shi, JJ	1
Gao, B	1
Chen, YK	1
Yang, HC	1
Chen, HL	1
Li, YC	1
Zhen, XC	1
Abrams, RPM	1
Yasgar, A	1
Teramoto, T	1
Lee, MH	1
Dorjsuren, D	1
Eastman, RT	1
Malik, N	1
Zakharov, AV	1
Li, W	3
Bachani, M	1
Brimacombe, K	1
Steiner, JP	1
Hall, MD	1
Balasubramanian, A	1
Jadhav, A	1
Padmanabhan, R	1
Simeonov, A	1
Nath, A	1
Chimienti, G	1
Orlando, A	1
Russo, F	1
D'Attoma, B	1
Aragno, M	1
Aimaretti, E	1
Lezza, AMS	1
Pesce, V	1
Mahmoud, AA	1
Elfiky, AM	1
Abo-Zeid, FS	2
Nikmard, F	1
Hosseini, E	1
Bakhtiyari, M	1
Ashrafi, M	1
Amidi, F	2
Aflatoonian, R	1
Peng, F	1
Hu, Y	1
Peng, S	1
Zeng, N	1
Shi, L	2
Zhang, Y	1
Xu, L	2
Ullah, A	1
Wang, MJ	1
Yang, JP	1
Adu-Gyamfi, EA	1
Czika, A	1
Sah, SK	1
Feng, Q	1
Wang, YX	4
El Leithy, AA	1
Al-Karmalawy, AA	1
Youssif, OM	1
Ebrahim, YA	1
Khalifa, AS	1
Elkaeed, EB	1
Xiao, N	1
Wang, J	1
Wang, T	1
Xiong, X	1
Zhou, J	2
Su, X	1
Peng, J	1
Yang, C	1
Li, X	4
Lin, G	1
Lu, G	1
Gong, F	1
Cheng, L	1
Ye, R	2
Yan, C	1
Zhou, H	2
Zhang, C	3
Huang, Y	3
Dong, M	2
Zhang, H	3
Lin, J	2
Jiang, X	1
Yuan, S	1
Chen, L	3
Jiang, R	1
Cheng, Z	1
Zheng, K	1
Yu, A	1
Zhang, Q	1
Quan, LH	1
Jin, W	2
Poojary, PS	1
Nayak, G	1
Panchanan, G	1
Rao, A	1
Kundapur, SD	1
Kalthur, SG	1
Mutalik, S	1
Adiga, SK	1
Zhao, Y	1
Bakkum-Gamez, J	1
Chang, AY	1
DeStephano, C	1
Sherman, M	1
Kannan, N	1
Kalthur, G	1
Ren, J	1
Tan, G	1
Ren, X	1
Lu, W	1
Peng, Q	1
Tang, J	1
Wang, Y	5
Xie, B	1
Wang, M	1
Chen, Y	3
Gao, Q	2
Hou, L	1
Feng, X	1
Türkmen, NB	1
Yüce, H	1
Aydın, M	1
Taşlıdere, A	1
Doğan, A	1
Özek, DA	1
Hayal, TB	1
Yaşar, Ş	1
Çiftçi, O	1
Ünüvar, S	1
Liu, S	2
Yao, Q	2
Wu, H	2
Sun, C	1
Bai, W	1
Kang, J	4
Zhao, B	1
Sozen, B	1
Ozekinci, M	1
Erman, M	1
Gunduz, T	1
Demir, N	1
Akouri, R	1
Jafari Khorchani, M	1
Zal, F	2
Neisy, A	2
Tao, T	1
Liu, GJ	1
Shi, X	1
Zhou, Y	1
Lu, Y	1
Gao, YY	1
Zhang, XS	1
Wang, H	4
Wu, LY	1
Chen, CL	1
Zhuang, Z	1
Hang, CH	1
Cao, J	1
Yang, Z	2
Zhao, J	1
Ma, H	1
Panagiotakopoulou, V	1
Botsakis, K	1
Delis, F	1
Mourtzi, T	1
Tzatzarakis, MN	1
Dimopoulou, A	1
Poulia, N	1
Antoniou, K	1
Stathopoulos, GT	1
Matsokis, N	1
Charalampopoulos, I	1
Gravanis, A	1
Angelatou, F	1
Emidio, GD	1
Placidi, M	1
Rea, F	1
Rossi, G	1
Falone, S	1
Cristiano, L	1
Nottola, S	1
D'Alessandro, AM	1
Amicarelli, F	1
Palmerini, MG	1
Tatone, C	1
Safaei, Z	1
Bakhshalizadeh, S	2
Nasr-Esfahani, MH	1
Akbari Sene, A	1
Najafzadeh, V	1
Soleimani, M	1
Shirazi, R	2
Fatemi Abhari, SM	1
Khanbabaei, R	1
Hayati Roodbari, N	1
Parivar, K	1
Yaghmaei, P	1
Olaniyan, OT	1
Bamidele, O	1
Adetunji, CO	1
Priscilla, B	1
Femi, A	1
Ayobami, D	1
Okotie, G	1
Oluwaseun, I	1
Olugbenga, E	1
Mali, PC	1
Balapattabi, K	1
Little, JT	1
Bachelor, ME	1
Cunningham, RL	1
Cunningham, JT	1
Doretto-Silva, L	1
Steiner, ML	1
Veridiano, JM	1
Petri, G	1
Luz, MCB	1
Neofiti-Papi, B	1
Bianco, B	1
Fonseca, FLA	1
Toledo, OMS	1
Fernandes, CE	1
Pompei, LM	1
Dehnad, A	1
Fan, W	1
Jiang, JX	1
Fish, SR	1
Li, Y	2
Das, S	1
Mozes, G	1
Wong, KA	1
Olson, KA	1
Charville, GW	1
Ali, M	1
Török, NJ	1
Fu, XP	1
Fu, BB	1
Wei, KN	1
Liu, Y	2
Liao, BQ	1
He, SW	1
Wang, YL	1
Chen, MH	1
Lin, YH	1
Li, FP	1
Hong, ZW	1
Huang, XH	1
Xu, CL	1
Wang, HL	1
Gisela S, B	1
M Virginia, A	1
Gabriela A, A	1
M Virginia, T	1
Enrique H, L	1
Laura, K	1
Véronica L, B	1
Tan, Y	1
Wang, X	1
Zhu, M	2
Guo, Z	1
Chen, X	2
Feng, P	1
Yu, Q	2
Wu, LM	1
Zhan, Y	1
Liu, AH	1
Shen, HF	1
Wang, YF	1
Wang, LY	1
Tao, ZB	1
Wang, YQ	1
Li, SJ	2
Yin, TL	2
Yang, J	3
Cheng, Y	1
Eini, F	1
Novin, MG	1
Joharchi, K	1
Hosseini, A	1
Nazarian, H	1
Piryaei, A	1
Bidadkosh, A	1
Hu, T	1
Yuan, X	1
Wei, G	1
Lim, W	1
Liu, Q	1
Lee, HJ	1
Du, SY	1
Ding, M	1
Dou, X	1
Zhang, FF	1
Wu, ZY	1
Qian, SW	1
Zhang, W	2
Tang, QQ	1
Xu, CJ	1
Boghozian, R	1
McKenzie, BA	1
Saito, LB	1
Mehta, N	1
Branton, WG	1
Lu, J	1
Baker, GB	1
Noorbakhsh, F	1
Power, C	1
Singh, A	2
Bora, P	1
Krishna, A	2
Zhao, H	1
Zhou, D	1
Liu, D	1
Chu, S	1
Zhang, S	1
Wang, D	1
Wang, W	2
Liang, Q	1
He, X	1
Xia, Y	1
Shen, S	2
Shabani Nashtaei, M	1
Pyun, BJ	1
Yang, H	1
Sohn, E	1
Yu, SY	1
Lee, D	1
Jung, DH	1
Ko, BS	1
Lee, HW	1
Yang, YL	1
Sun, LF	1
Yu, Y	1
Xiao, TX	1
Wang, BB	1
Ren, PG	1
Tang, HR	1
Zhang, JV	1
Bracho, GS	1
Altamirano, GA	1
Kass, L	1
Luque, EH	1
Bosquiazzo, VL	1
Furat Rencber, S	1
Kurnaz Ozbek, S	1
Eraldemır, C	1
Sezer, Z	1
Kum, T	1
Ceylan, S	1
Guzel, E	1
Roggero, E	1
Del Rey, A	1
Wildmann, J	1
Besedovsky, H	1
Seghatoleslam, A	1
Alaee, S	1
Dou, L	1
Zheng, Y	1
Li, L	1
Gui, X	1
Yu, M	1
Guo, Y	1
Zhou, DN	1
Ding, JL	1
Ye, H	1
Seow, KM	1
Ting, CH	1
Huang, SW	1
Ho, LT	1
Juan, CC	1
Shi, Y	1
Kong, X	1
Yin, H	1
Velez, LM	1
Abruzzese, GA	1
Heber, MF	1
Ferreira, SR	1
Motta, AB	4
Zheng, Q	1
Sun, D	1
Cui, X	1
Chen, S	1
Bulbul, A	1
Yan, Q	1
Zhang, YT	1
Xue, JJ	1
Wang, Q	1
Cheng, SY	1
Chen, ZC	1
Li, HY	1
Shan, JJ	1
Cheng, KL	1
Zeng, WJ	1
Shen, Q	2
Bi, H	1
Yu, F	1
Fan, L	1
Jia, X	1
Demacopulo, B	1
Kreimann, EL	1
Xue, J	1
Liu, P	1
Li, K	1
Sha, L	1
Yang, X	1
Zhu, L	2
Wang, Z	1
Dong, Y	1
Zhang, L	1
Lei, H	1
Zhang, X	2
Dong, X	1
Schmitz, D	2
Lendemans, S	1
Oberbeck, R	3
McCommis, KS	1
Douglas, DL	1
Krenz, M	1
Baines, CP	1
Zhu, WJ	1
Xie, BG	1
Jang, M	2
Lee, MJ	2
Lee, JM	1
Bae, CS	2
Kim, SH	1
Ryu, JH	1
Cho, IH	2
Maurya, VK	2
Sangappa, C	1
Kumar, V	2
Mahfooz, S	1
Rajender, S	1
Jha, RK	2
Eleawa, S	1
Bin-Jaliah, I	1
Alkhateeb, M	1
Bayoumy, NM	1
Alessa, R	1
Sakr, HF	1
Kilic, FS	1
Kulluk, D	1
Musmul, A	1
Lichte, P	1
Pfeifer, R	1
Werner, BE	1
Ewers, P	1
Tohidnezhad, M	1
Pufe, T	1
Hildebrand, F	3
Pape, HC	3
Kobbe, P	2
Arumugam, A	1
Lissner, EA	1
Lakshmanaswamy, R	1
Al-Banna, N	1
Pavlovic, D	1
Sharawi, N	1
Bac, VH	1
Jaskulski, M	1
Balzer, C	1
Weber, S	1
Nedeljkov, V	1
Lehmann, C	1
Khan, RS	1
Dine, K	1
Luna, E	1
Ahlem, C	1
Shindler, KS	1
Shohat-Tal, A	1
Sen, A	1
Barad, DH	1
Kushnir, V	1
Gleicher, N	1
Yabuki, Y	1
Shinoda, Y	1
Izumi, H	1
Ikuno, T	1
Shioda, N	1
Fukunaga, K	1
Gui, Y	1
Qiu, X	1
Xu, Y	1
Li, D	1
Wang, L	1
Huang, K	2
Bao, JP	2
Jennings, GJ	1
Wu, LD	3
Tao, X	1
Ge, SQ	1
Zhang, EH	1
Zhang, B	1
Tessaro, I	1
Modina, SC	1
Franciosi, F	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men Title Changed With New Protocol (12/14/09): Hormonal Regulation of HDL-C in Men[NCT00729859]	Phase 2	31 participants (Actual)	Interventional	2008-12-31	Completed
The Effect of Dihydrotestosterone (DHT) on Prostate Tissue Androgen Concentrations and Inflammation in Normal Men[NCT00490022]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2007-06-30	Completed
A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471]		45 participants (Anticipated)	Observational	2021-06-30	Not yet recruiting
Etude de l'Activite (Efficacite et Tolerance) de l'Association de la Chloroquine Avec la Dehydroepiandrosterone-Sulfate (Dheas) Dans le Traitement de l'Acces Palustre Simple A Plasmodium Falciparum[NCT00442403]	Phase 3	200 participants	Interventional	2002-04-30	Suspended (stopped due to At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of CD33 + CD134+ cells as a percentage of all lymphocytes (NCT00729859)
Timeframe: Baseline, Day 28

Estradiol Concentration

Fasting Lipid Levels

Fasting Serum Insulin

Follicle Stimulating Hormone (FSH)

Homeostasis Model of Insulin Resistance (HOMA-IR)

Intervention	percentage of all lymphocytes (Mean)
	Baseline	Day 28
Group 1: Acyline + Placebo Gel + Placebo Pill	0.101	0.081

Intervention	pmol/L (Mean)
	Baseline	Day 28
Group 1: Acyline + Placebo Gel, Placebo Pill	95.4	31.9
Group 2: Acyline, Testosterone Gel	117.8	109.0
Group 3: Acyline, Testosterone Gel, Anastrozole Pill	96.3	36.5

Intervention	mmol/L (Mean)
	Total cholesterol Day 0	Total cholesterol Day 28	Total cholesterol Day 56	LDL choesterol Day 0	LDL cholesterol Day 28	LDL cholesterol Day 56	HDL cholesterol Day 0	HDL cholesterol Day 28	HDL cholesterol Day 56	Triglycerides Day 0	Triglycerides Day 28	Triglycerides Day 56
Group 1: Acyline + Placebo Gel, Placebo Pill	4.97	5.44	4.95	2.95	3.29	2.87	1.19	1.37	1.19	1.79	1.73	1.89
Group 2: Acyline, Testosterone Gel, Placebo Pill	4.48	4.51	4.14	2.77	2.80	2.49	1.32	1.32	1.32	0.82	0.86	0.80
Group 3: Acyline, Testosterone Gel, Oral Anastrozole	4.56	4.56	4.27	2.67	2.75	2.51	1.40	1.32	1.30	1.08	1.08	1.02

Intervention	picomolar (Mean)
	Baseline	Day 28	Day 56
Group 1: Acyline + Placebo Gel, Placebo Pill	54	69	54
Group 2: Acyline, Testosterone Gel, Placebo Pill	65	59	64
Group 3: Acyline, Testosterone Gel, Oral Anastrozole	50	42	50

Intervention	IU/L (Mean)
	Baseline	Day 28
Group 1: Acyline + Placebo Gel, Placebo Pill	4.2	0.42
Group 2: Acyline, Testosterone Gel	2.9	0.39
Group 3: Acyline, Testosterone Gel, Anastrazole Pill	2.5	0.87

HOMA IR is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher HOMA IR numbers are associated with increased insulin resistance and decreased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56

Luteinizing Hormone Concentration (LH)

Quantitative Insulin Sensitivity Check Index (QUICKI)

Intervention	HOMA score (Mean)
	Baseline	Day 28	Day 56
Group 1: Acyline + Placebo Gel, Placebo Pill	1.8	2.4	2.2
Group 2: Acyline, Testosterone Gel, Placebo Pill	2.0	1.9	1.9
Group 3: Acyline, Testosterone Gel, Oral Anastrozole	1.6	1.4	1.7

Intervention	IU/L (Mean)
	Baseline	Day 28
Group 1: Acyline + Placebo Gel, Placebo Pill	4.3	0.31
Group 2: Acyline, Testosterone Gel	4.7	0.69
Group 3: Acyline, Testosterone Gel, Anastrozole	4.4	1.55

QUICKI is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher QUICKI are associated with decreased insulin resistance and increased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56

Sex Hormone Binding Globulin (SHBG)

Testosterone Concentration

Prostate Epithelial Cell Proliferation

Intervention	QUICKI index (Mean)
	Baseline	Day 28	Day 56
Group 1: Acyline + Placebo Gel, Placebo Pill	0.36	0.34	0.35
Group 2: Acyline, Testosterone Gel, Placebo Pill	0.35	0.35	0.35
Group 3: Acyline, Testosterone Gel, Oral Anastrozole	0.36	0.38	0.36

Intervention	nmol/L (Mean)
	Baseline	Day 28
Group 1: Acyline + Placebo Gel, Placebo Pill	34.9	37.5
Group 2: Acyline, Testosterone Gel	23.0	22.1
Group 3: Acyline, Testosterone Gel, Anastrozole Pill	27.6	25.1

Intervention	nmol/L (Mean)
	Baseline testosterone concentration	Day 28 testosterone concentration
Group 1: Acyline + Placebo Gel, Placebo Pill	15.4	0.8
Group 2: Acyline, Testosterone Gel	16.3	17.8
Group 3: Acyline, Testosterone Gel, Anastrozole	16.5	19.0

Prostate epithelial cell proliferation in the prostate biopsy tissue was measured using Ki-67 immunohistochemical staining of prostate epithelium as a marker of cell proliferation (values are number of Ki-67 positive stained cells per 100 prostate epithelial cells). The placebo and treatment groups were compared. (NCT00490022)
Timeframe: 28-days

Prostate Tissue DHT and Testosterone Levels After 28 Days of Treatment With Dihydrotestosterone [DHT] Gel Versus Placebo Gel.

Intervention	#pos.Ki-67cells per100 prst. epth cells (Mean)
Placebo DHT Gel	1.3
DHT Gel	0.7

After 4 weeks of either daily dihydrotestosterone transdermal gel or placebo gel, subjects underwent a prostate biopsy. Intraprostatic hormone concentrations, specifically DHT and Testosterone, were measured. Unit of measure is ng/g. (NCT00490022)
Timeframe: 28-days

Reviews

Trials

Other Studies

154 other studies available for dehydroepiandrosterone and Disease Models, Animal

Article	Year
Glucocorticoids and sympathetic neurotransmitters modulate the acute immune response to Trypanosoma cruzi. Annals of the New York Academy of Sciences, 2019, Volume: 1437, Issue:1 Topics: Animals; CD8-Positive T-Lymphocytes; Chagas Disease; Cytokines; Dehydroepiandrosterone; Disease Mode	2019
Genetics of androgen metabolism in women with infertility and hypoandrogenism. Nature reviews. Endocrinology, 2015, Volume: 11, Issue:7 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgens; Animals; Aromatase; Dehydroepiandrosterone; Diseas	2015
7-Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases. Autoimmunity reviews, 2009, Volume: 8, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Clinical Trials as Topic; Colitis; Dehyd	2009
Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Women's health (London, England), 2010, Volume: 6, Issue:2 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Estrogens; Female; Gonadal Steroid Hormones	2010
Dehydroepiandrosterone to induce murine models for the study of polycystic ovary syndrome. The Journal of steroid biochemistry and molecular biology, 2010, Volume: 119, Issue:3-5 Topics: Androgens; Animals; Dehydroepiandrosterone; Disease Models, Animal; Embryo Loss; Female; Humans; Hyp	2010
Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacology & therapeutics, 2010, Volume: 126, Issue:2 Topics: Animals; Apoptosis; Cell Proliferation; Constriction, Pathologic; Dehydroepiandrosterone; Disease Mo	2010
The role of dehydroepiandrosterone (DHEA) in drug-seeking behavior. Neuroscience and biobehavioral reviews, 2010, Volume: 35, Issue:2 Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Disease Models, Animal; Drug-Seekin	2010
Neurobiology of resilience. Nature neuroscience, 2012, Volume: 15, Issue:11 Topics: Animals; Brain; Dehydroepiandrosterone; Disease Models, Animal; Early Growth Response Transcription	2012
Gender dimorphism in immune responses following trauma and hemorrhage. Immunologic research, 2002, Volume: 26, Issue:1-3 Topics: Androgens; Animals; Dehydroepiandrosterone; Disease Models, Animal; Estrogens; Female; Gonadal Stero	2002
Androgens and coronary artery disease. Endocrine reviews, 2003, Volume: 24, Issue:2 Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor	2003
Androgens and coronary artery disease. Endocrine reviews, 2003, Volume: 24, Issue:2 Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor	2003
Androgens and coronary artery disease. Endocrine reviews, 2003, Volume: 24, Issue:2 Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor	2003
Androgens and coronary artery disease. Endocrine reviews, 2003, Volume: 24, Issue:2 Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor	2003
[Effects of sigma receptor ligands on psychiatric disorders]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2003, Volume: 23, Issue:5 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Humans; Learning Disabilities; Ligands; Mem	2003
[Neuroendocrine immunomodulation]. Vestnik Rossiiskoi akademii meditsinskikh nauk, 2007, Issue:9 Topics: Animals; Cells, Cultured; Cytokines; Dehydroepiandrosterone; Disease Models, Animal; Growth Hormone;	2007
Polycystic ovarian disease. Fertility and sterility, 1981, Volume: 35, Issue:4 Topics: Adrenal Cortex; Animals; Dehydroepiandrosterone; Dexamethasone; Disease Models, Animal; Female; Foll	1981
Calorie restriction in primates: will it work and how will we know? Journal of the American Geriatrics Society, 1999, Volume: 47, Issue:7 Topics: Aging; Analysis of Variance; Animals; Biomarkers; Body Weight; Cardiovascular Diseases; Cause of Dea	1999
Polycystic ovary syndrome--searching for an animal model. Journal of medicine, 1998, Volume: 29, Issue:5-6 Topics: Androgens; Animals; Chorionic Gonadotropin; Dehydroepiandrosterone; Disease Models, Animal; Estradio	1998
Dehydroepiandrosterone in systemic lupus erythematosus. Rheumatic diseases clinics of North America, 2000, Volume: 26, Issue:2 Topics: Adjuvants, Immunologic; Animals; Clinical Trials as Topic; Dehydroepiandrosterone; Disease Models, A	2000
Androgen effect on insulin action and glucose metabolism. Mayo Clinic proceedings, 2000, Volume: 75 Suppl Topics: Androgens; Animals; Dehydroepiandrosterone; Disease Models, Animal; Drug Evaluation, Preclinical; Gl	2000
[Neuropsychic effects of dehydroepiandrosterone]. Annales de medecine interne, 2001, Volume: 152 Suppl 3 Topics: Affect; Aging; Animals; Attention; Cardiovascular Diseases; Dehydroepiandrosterone; Dehydroepiandros	2001
Interrelationship between excessive levels of circulating androgens in blood and ovulatory failure. The Journal of reproductive medicine, 1976, Volume: 17, Issue:2 Topics: Animals; Anovulation; Chemoreceptor Cells; Dehydroepiandrosterone; Disease Models, Animal; Estradiol	1976
Animal models for study of polycystic ovaries and ovarian atresia. Advances in experimental medicine and biology, 1987, Volume: 219 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Follicular Atresia; Follicular Phas	1987
Polycystic ovarian disease: animal models. Endocrinology and metabolism clinics of North America, 1988, Volume: 17, Issue:4 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Endorphins; Estradiol; Female; Hypothalamus	1988
Adrenocortical insufficiency. Clinics in endocrinology and metabolism, 1985, Volume: 14, Issue:4 Topics: Addison Disease; Adrenal Insufficiency; Adrenocorticotropic Hormone; Aldosterone; Androstenedione; A	1985
Inhibition of 3 -hydroxy- 5 -steroid dehydrogenase. Gynecologic investigation, 1971, Volume: 2, Issue:1 Topics: Adrenal Hyperplasia, Congenital; Androstenes; Animals; Antibodies; Cell Differentiation; Dehydroepia	1971

Article	Year
Synthesis of 5α-cholestan-6-one derivatives and their inhibitory activities of NO production in activated microglia: discovery of a novel neuroinflammation inhibitor. Bioorganic & medicinal chemistry letters, 2014, Feb-15, Volume: 24, Issue:4 Topics: Animals; Cell Line; Cell Survival; Cholestanones; Crystallography, X-Ray; Disease Models, Animal; Do	2014
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49 Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr	2020
The Mitochondrial Trigger in an Animal Model of Nonalcoholic Fatty Liver Disease. Genes, 2021, 09-18, Volume: 12, Issue:9 Topics: Animals; Antioxidants; Autophagy; Dehydroepiandrosterone; Diet, High-Fat; Disease Models, Animal; DN	2021
The anti-androgenic effect of quercetin on hyperandrogenism and ovarian dysfunction induced in a dehydroepiandrosterone rat model of polycystic ovary syndrome. Steroids, 2022, Volume: 177 Topics: Androgen Antagonists; Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Hyperandrogen	2022
The boosting effects of melatonin on the expression of related genes to oocyte maturation and antioxidant pathways: a polycystic ovary syndrome- mouse model. Journal of ovarian research, 2022, Jan-20, Volume: 15, Issue:1 Topics: Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Bone Morphogenetic Protein 15; Dehydro	2022
Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis. Annals of medicine, 2022, Volume: 54, Issue:1 Topics: Animals; Apigenin; Dehydroepiandrosterone; Disease Models, Animal; Female; Humans; Polycystic Ovary	2022
Comparative study of DHEA and letrozole induced polycystic ovary syndrome in post-pubertal rats. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2022, Volume: 38, Issue:5 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Follicle Stimulating Hormone; Human	2022
Ovarian inflammatory mRNA profiles of a dehydroepiandrosterone plus high-fat diet-induced polycystic ovary syndrome mouse model. Reproductive biomedicine online, 2022, Volume: 44, Issue:5 Topics: Animals; Dehydroepiandrosterone; Diet, High-Fat; Disease Models, Animal; Female; Humans; Inflammatio	2022
Spirulina therapeutic potentiality in polycystic ovarian syndrome management using DHEA-induced rat model. European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:8 Topics: Animals; bcl-2-Associated X Protein; Dehydroepiandrosterone; Disease Models, Animal; Female; Humans;	2022
Metformin abrogates pathological TNF-α-producing B cells through mTOR-dependent metabolic reprogramming in polycystic ovary syndrome. eLife, 2022, 06-24, Volume: 11 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Humans; Metformin; Mice; Polycystic	2022
Brown adipose tissue activation with ginsenoside compound K ameliorates polycystic ovary syndrome. British journal of pharmacology, 2022, Volume: 179, Issue:18 Topics: Adipose Tissue, Brown; Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Ginsenosides	2022
Distinctions in PCOS Induced by Letrozole Vs Dehydroepiandrosterone With High-fat Diet in Mouse Model. Endocrinology, 2022, 09-01, Volume: 163, Issue:9 Topics: Animals; Body Weight; Dehydroepiandrosterone; Diet, High-Fat; Disease Models, Animal; Female; Humans	2022
The PNA mouse may be the best animal model of polycystic ovary syndrome. Frontiers in endocrinology, 2022, Volume: 13 Topics: Animals; Dehydroepiandrosterone; Diet, High-Fat; Disease Models, Animal; Female; Humans; Mice; Polyc	2022
HDAC5 inhibits ovarian angiogenesis in dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome. Folia histochemica et cytobiologica, 2022, Volume: 60, Issue:3 Topics: Angiogenesis Inducing Agents; Angiopoietins; Animals; Catalase; Dehydroepiandrosterone; Disease Mode	2022
Nerolidol attenuates dehydroepiandrosterone-induced polycystic ovary syndrome in rats by regulating oxidative stress and decreasing apoptosis. Life sciences, 2023, Feb-15, Volume: 315 Topics: Animals; Apoptosis; Dehydroepiandrosterone; Disease Models, Animal; Female; Humans; Inflammation; Ox	2023
Effects of a ketogenic diet on reproductive and metabolic phenotypes in mice with polycystic ovary syndrome†. Biology of reproduction, 2023, 04-11, Volume: 108, Issue:4 Topics: Animals; Dehydroepiandrosterone; Diet, Ketogenic; Disease Models, Animal; Female; Humans; Inflammati	2023
Dehydroepiandrosterone-induced polycystic ovary syndrome mouse model requires continous treatments to maintain reproductive phenotypes. Journal of ovarian research, 2023, Oct-25, Volume: 16, Issue:1 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Humans; Infant, Newborn; Mice; Mice	2023
Dehydroepiandrosterone supplementation attenuates ovarian ageing in a galactose-induced primary ovarian insufficiency rat model. Journal of assisted reproduction and genetics, 2019, Volume: 36, Issue:10 Topics: Aging; Animals; Dehydroepiandrosterone; Dietary Supplements; Disease Models, Animal; Female; Galacto	2019
The phytoestrogen, quercetin, in serum, uterus and ovary as a potential treatment for dehydroepiandrosterone-induced polycystic ovary syndrome in the rat. Reproduction, fertility, and development, 2020, Volume: 32, Issue:3 Topics: Adiponectin; Animals; Aromatase; Dehydroepiandrosterone; Disease Models, Animal; Estradiol; Female;	2020
DHEA Attenuates Microglial Activation via Induction of JMJD3 in Experimental Subarachnoid Haemorrhage. Journal of neuroinflammation, 2019, Nov-28, Volume: 16, Issue:1 Topics: Animals; Brain; Cells, Cultured; Dehydroepiandrosterone; Disease Models, Animal; Jumonji Domain-Cont	2019
Effect of dehydroepiandrosterone on the immune response and gut microbiota in dextran sulfate sodium-induced colitis mice. Molecular immunology, 2020, Volume: 118 Topics: Animals; Anti-Inflammatory Agents; Colitis; Colon; Cytokines; Dehydroepiandrosterone; Dextran Sulfat	2020
Anti-neuroinflammatory, protective effects of the synthetic microneurotrophin BNN-20 in the advanced dopaminergic neurodegeneration of "weaver" mice. Neuropharmacology, 2020, 03-15, Volume: 165 Topics: Animals; Anti-Inflammatory Agents; Brain-Derived Neurotrophic Factor; Dehydroepiandrosterone; Diseas	2020
Methylglyoxal-Dependent Glycative Stress and Deregulation of SIRT1 Functional Network in the Ovary of PCOS Mice. Cells, 2020, 01-14, Volume: 9, Issue:1 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Glycation End Products, Advanced; G	2020
Vitamin D3 affects mitochondrial biogenesis through mitogen-activated protein kinase in polycystic ovary syndrome mouse model. Journal of cellular physiology, 2020, Volume: 235, Issue:9 Topics: Animals; Apoptosis; Catalase; Cholecalciferol; Dehydroepiandrosterone; Disease Models, Animal; Femal	2020
Curcumin-loaded super-paramagnetic iron oxide nanoparticle affects on apoptotic factors expression and histological changes in a prepubertal mouse model of polycystic ovary syndrome-induced by dehydroepiandrosterone - A molecular and stereological study. Life sciences, 2020, May-15, Volume: 249 Topics: Animals; Antioxidants; Apoptosis; Caspase 3; Curcumin; Dehydroepiandrosterone; Disease Models, Anima	2020
Quercetin modulates granulosa cell mRNA androgen receptor gene expression in dehydroepiandrosterone-induced polycystic ovary in Wistar rats via metabolic and hormonal pathways. Journal of basic and clinical physiology and pharmacology, 2020, Mar-11, Volume: 31, Issue:4 Topics: Adjuvants, Immunologic; Animals; Antioxidants; Dehydroepiandrosterone; Disease Models, Animal; Femal	2020
Sex Differences in the Regulation of Vasopressin and Oxytocin Secretion in Bile Duct-Ligated Rats. Neuroendocrinology, 2021, Volume: 111, Issue:3 Topics: Animals; Arginine Vasopressin; Bile Ducts; Dehydroepiandrosterone; Disease Models, Animal; Estradiol	2021
White, brown, and bone marrow adipose tissue behavior in DHEA-induced PCOS mice. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2021, Volume: 37, Issue:1 Topics: Adipose Tissue; Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Insulin Resistance;	2021
AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes. The Journal of clinical investigation, 2020, 08-03, Volume: 130, Issue:8 Topics: Animals; Ascorbic Acid; Cholecalciferol; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Disease	2020
Pachymic acid protects oocyte by improving the ovarian microenvironment in polycystic ovary syndrome mice†. Biology of reproduction, 2020, 10-29, Volume: 103, Issue:5 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Metformin; Mice; Oocytes; Ovary; Po	2020
Androgen receptor and uterine histoarchitecture in a PCOS rat model. Molecular and cellular endocrinology, 2020, 12-01, Volume: 518 Topics: Animals; Animals, Newborn; Aquaporins; Collagen; Dehydroepiandrosterone; Disease Models, Animal; Est	2020
Paeoniflorin attenuates DHEA-induced polycystic ovary syndrome via inactivation of TGF-β1/Smads signaling pathway Aging, 2021, 02-26, Volume: 13, Issue:5 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Estrous Cycle; Female; Glucosides; Monoterp	2021
Short-term rapamycin administration elevated testosterone levels and exacerbated reproductive disorder in dehydroepiandrosterone-induced polycystic ovary syndrome mice. Journal of ovarian research, 2021, May-04, Volume: 14, Issue:1 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Humans; Mice; Polycystic Ovary Synd	2021
Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats. Peptides, 2021, Volume: 145 Topics: Animals; Body Weight; Dehydroepiandrosterone; Disease Models, Animal; Female; Gene Expression Regula	2021
ATP synthase β-subunit abnormality in pancreas islets of rats with polycystic ovary syndrome and type 2 diabetes mellitus. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2017, Volume: 37, Issue:2 Topics: Adenosine Triphosphate; Animals; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Diet, High-Fat;	2017
Intracytoplasmic oxidative stress reverses epigenetic modifications in polycystic ovary syndrome. Reproduction, fertility, and development, 2017, Volume: 29, Issue:12 Topics: Acetylation; Animals; Dehydroepiandrosterone; Disease Models, Animal; DNA Methylation; Estradiol; Fe	2017
Brown adipose tissue activation by rutin ameliorates polycystic ovary syndrome in rat. The Journal of nutritional biochemistry, 2017, Volume: 47 Topics: Adipose Tissue, Brown; Animals; Anovulation; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity A	2017
The BMP4-Smad signaling pathway regulates hyperandrogenism development in a female mouse model. The Journal of biological chemistry, 2017, 07-14, Volume: 292, Issue:28 Topics: Androgens; Animals; Bone Morphogenetic Protein 4; Cells, Cultured; Dehydroepiandrosterone; Disease M	2017
Suppressed oligodendrocyte steroidogenesis in multiple sclerosis: Implications for regulation of neuroinflammation. Glia, 2017, Volume: 65, Issue:10 Topics: Animals; Astrocytes; Case-Control Studies; Cells, Cultured; Central Nervous System; Cytokines; Dehyd	2017
Systemic adiponectin treatment reverses polycystic ovary syndrome-like features in an animal model. Reproduction, fertility, and development, 2018, Volume: 30, Issue:4 Topics: Adiponectin; Androgens; Animals; Body Mass Index; Dehydroepiandrosterone; Disease Models, Animal; Fe	2018
Beneficial effects of Heqi san on rat model of polycystic ovary syndrome through the PI3K/AKT pathway. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2017, Oct-11, Volume: 25, Issue:1 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; DNA-Binding Proteins; Drugs, Chinese Herbal	2017
DHEA-induced ovarian hyperfibrosis is mediated by TGF-β signaling pathway. Journal of ovarian research, 2018, Jan-10, Volume: 11, Issue:1 Topics: Animals; Biomarkers; Dehydroepiandrosterone; Disease Models, Animal; Estrous Cycle; Female; Fibrosis	2018
Vitamin D3 regulates steroidogenesis in granulosa cells through AMP-activated protein kinase (AMPK) activation in a mouse model of polycystic ovary syndrome. Cell biochemistry and function, 2018, Volume: 36, Issue:4 Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Cholecalciferol; Dehydroepiandrosterone; Di	2018
Tetragonia tetragonioides (Pall.) Kuntze Regulates Androgen Production in a Letrozole-Induced Polycystic Ovary Syndrome Model. Molecules (Basel, Switzerland), 2018, May-14, Volume: 23, Issue:5 Topics: Aizoaceae; Androgens; Animals; Cell Line; Cell Survival; Cyclic AMP Response Element-Binding Protein	2018
Deficiency of Gpr1 improves steroid hormone abnormality in hyperandrogenized mice. Reproductive biology and endocrinology : RB&E, 2018, May-24, Volume: 16, Issue:1 Topics: Animals; Cells, Cultured; Dehydroepiandrosterone; Disease Models, Animal; Estradiol; Female; Hyperan	2018
Hyperandrogenism Induces Histo-Architectural Changes in the Rat Uterus. Reproductive sciences (Thousand Oaks, Calif.), 2019, Volume: 26, Issue:5 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Estrogen Receptor alpha; Female; Hyperandro	2019
Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. Journal of ovarian research, 2018, Jun-29, Volume: 11, Issue:1 Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Count; Dehydroepiandrosterone; Disease Model	2018
Amelioration by quercetin of insulin resistance and uterine GLUT4 and ERα gene expression in rats with polycystic ovary syndrome (PCOS). Reproduction, fertility, and development, 2019, Volume: 31, Issue:2 Topics: Animals; Antioxidants; Dehydroepiandrosterone; Disease Models, Animal; Estrogen Receptor alpha; Fema	2019
The effect of cinnamon on polycystic ovary syndrome in a mouse model. Reproductive biology and endocrinology : RB&E, 2018, Oct-19, Volume: 16, Issue:1 Topics: Animals; Cinnamomum zeylanicum; Dehydroepiandrosterone; Disease Models, Animal; Female; Humans; Insu	2018
MIF May Participate in Pathogenesis of Polycystic Ovary Syndrome in Rats through MAPK Signalling Pathway. Current medical science, 2018, Volume: 38, Issue:5 Topics: Animals; Dehydroepiandrosterone; Diet, High-Fat; Disease Models, Animal; Fasting; Female; Humans; In	2018
The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome. Taiwanese journal of obstetrics & gynecology, 2018, Volume: 57, Issue:5 Topics: Adiposity; Animals; Blood Glucose; Dehydroepiandrosterone; Disease Models, Animal; Estrous Cycle; Fa	2018
Effect of Hawthorn Leaf Flavonoids in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome in Rats. Pathobiology : journal of immunopathology, molecular and cellular biology, 2019, Volume: 86, Issue:2-3 Topics: Administration, Oral; Animals; Crataegus; Dehydroepiandrosterone; Disease Models, Animal; Female; Fl	2019
Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats. Pharmacological reports : PR, 2019, Volume: 71, Issue:1 Topics: Animals; Co-Repressor Proteins; Dehydroepiandrosterone; Disease Models, Animal; Estradiol; Female; H	2019
Dehydroepiandrosterone stimulates inflammation and impairs ovarian functions of polycystic ovary syndrome. Journal of cellular physiology, 2019, Volume: 234, Issue:5 Topics: Animals; Apoptosis; Cell Line; Dehydroepiandrosterone; Disease Models, Animal; Down-Regulation; Fema	2019
Dehydroepiandrosterone attenuates pulmonary artery and right ventricular remodeling in a rat model of pulmonary hypertension due to left heart failure. Life sciences, 2019, Feb-15, Volume: 219 Topics: Animals; Blotting, Western; Dehydroepiandrosterone; Disease Models, Animal; Echocardiography; Heart	2019
Nontargeted metabolomic analysis of skeletal muscle in a dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome. Molecular reproduction and development, 2019, Volume: 86, Issue:4 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Humans; Metabolomics; Mice; Muscle,	2019
Bisphenol S increases EZRIN expression and the detrimental effects induced by dehydroepiandrosterone in rat endometrium. Molecular and cellular endocrinology, 2019, 03-01, Volume: 483 Topics: Animals; Cell Proliferation; Cell Survival; Cytoskeletal Proteins; Dehydroepiandrosterone; Disease M	2019
Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice. Endocrine journal, 2019, Oct-28, Volume: 66, Issue:10 Topics: Animals; Anti-Inflammatory Agents; Bacteria; Biomarkers; Cytokines; Dehydroepiandrosterone; Diet, Hi	2019
Androstenediol modulates sepsis induced alterations of survival and immune functions in a murine model of sepsis. Medicinal chemistry (Shariqah (United Arab Emirates)), 2014, Volume: 10, Issue:2 Topics: Administration, Intravenous; Androstenediol; Animals; Apoptosis; Body Temperature; Cytokines; Dehydr	2014
Cardiac-specific hexokinase 2 overexpression attenuates hypertrophy by increasing pentose phosphate pathway flux. Journal of the American Heart Association, 2013, Nov-04, Volume: 2, Issue:6 Topics: Adrenergic alpha-Agonists; Animals; Animals, Newborn; Cardiomegaly; Cell Death; Cells, Cultured; Deh	2013
Expression of PPAR-γ in adipose tissue of rats with polycystic ovary syndrome induced by DHEA. Molecular medicine reports, 2014, Volume: 9, Issue:3 Topics: Adipose Tissue; Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Gene Expression Reg	2014
Oriental medicine Kyung-Ok-Ko prevents and alleviates dehydroepiandrosterone-induced polycystic ovarian syndrome in rats. PloS one, 2014, Volume: 9, Issue:2 Topics: Animals; Blood Glucose; Body Weight; Dehydroepiandrosterone; Disease Models, Animal; Drugs, Chinese	2014
Expression and activity of Rac1 is negatively affected in the dehydroepiandrosterone induced polycystic ovary of mouse. Journal of ovarian research, 2014, Mar-14, Volume: 7 Topics: Animals; Caveolin 1; Dehydroepiandrosterone; Disease Models, Animal; Down-Regulation; Estradiol; Fem	2014
The impact of dehydroepiandrosterone on indomethacin-induced gastric lesions in rats. Acta physiologica Hungarica, 2014, Volume: 101, Issue:1 Topics: Animals; Antioxidants; Catalase; Cytoprotection; Dehydroepiandrosterone; Disease Models, Animal; Gas	2014
Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice. Neurosciences (Riyadh, Saudi Arabia), 2014, Volume: 19, Issue:2 Topics: Adjuvants, Immunologic; Amphetamine; Animals; Apomorphine; Catalepsy; Central Nervous System Stimula	2014
Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model. European journal of medical research, 2014, May-19, Volume: 19 Topics: Adjuvants, Immunologic; Animals; Cytokines; Dehydroepiandrosterone; Disease Models, Animal; Femoral	2014
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model. Reproductive biology and endocrinology : RB&E, 2014, Jul-15, Volume: 12 Topics: Aging; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone; Disease M	2014
Combination of dehydroepiandrosterone and orthovanadate administration reduces intestinal leukocyte recruitment in models of experimental sepsis. Microvascular research, 2014, Volume: 95 Topics: Animals; Capillaries; Cell Adhesion; Chemotaxis, Leukocyte; Cytokines; Dehydroepiandrosterone; Disea	2014
HE3286 reduces axonal loss and preserves retinal ganglion cell function in experimental optic neuritis. Investigative ophthalmology & visual science, 2014, Aug-19, Volume: 55, Issue:9 Topics: Animals; Anti-Inflammatory Agents; Axons; Dehydroepiandrosterone; Disease Models, Animal; Encephalom	2014
Dehydroepiandrosterone administration improves memory deficits following transient brain ischemia through sigma-1 receptor stimulation. Brain research, 2015, Oct-05, Volume: 1622 Topics: Adenosine Triphosphate; Animals; Anisoles; Brain Ischemia; CA1 Region, Hippocampal; Calcium-Calmodul	2015
Bu-Shen-Ning-Xin decoction suppresses osteoclastogenesis via increasing dehydroepiandrosterone to prevent postmenopausal osteoporosis. Bioscience trends, 2015, Volume: 9, Issue:3 Topics: Animals; Cell Survival; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Disease Models, Anim	2015
The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study. BMC musculoskeletal disorders, 2015, Jul-31, Volume: 16 Topics: Animals; Antirheumatic Agents; Dehydroepiandrosterone; Disease Models, Animal; Disease Progression;	2015
Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:7 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Exenatide; Female; Gene Expression Regulati	2015
Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome. Journal of ovarian research, 2015, Oct-06, Volume: 8 Topics: Adjuvants, Immunologic; Administration, Oral; Analysis of Variance; Animals; Aromatase; Dehydroepian	2015
DHEA administration modulates stress-induced analgesia in rats. Physiology & behavior, 2016, Apr-01, Volume: 157 Topics: Analgesics; Analysis of Variance; Animals; Corticosterone; Dehydroepiandrosterone; Disease Models, A	2016
Effects of Oriental Medicine Kyung-Ok-Ko on Uterine Abnormality in Hyperandrogenized Rats. Rejuvenation research, 2016, Volume: 19, Issue:6 Topics: Animals; Apoptosis; CD4-Positive T-Lymphocytes; Dehydroepiandrosterone; Disease Models, Animal; Drug	2016
Effects of Exenatide on Metabolic Changes, Sexual Hormones, Inflammatory Cytokines, Adipokines, and Weight Change in a DHEA-Treated Rat Model. Reproductive sciences (Thousand Oaks, Calif.), 2016, Volume: 23, Issue:9 Topics: Adipokines; Animals; Body Weight; Cytokines; Dehydroepiandrosterone; Disease Models, Animal; Exenati	2016
Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy. Molecular cancer therapeutics, 2016, Volume: 15, Issue:5 Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers; Cell Line, Tumor; Cytochrome P-450 Enzyme Syst	2016
Salmeterol enhances the cardiac response to gene therapy in Pompe disease. Molecular genetics and metabolism, 2016, Volume: 118, Issue:1 Topics: alpha-Glucosidases; Animals; Clenbuterol; Dehydroepiandrosterone; Dependovirus; Disease Models, Anim	2016
Effects of gonadotropin-releasing hormone agonist and antagonist on ovarian activity in a mouse model for polycystic ovary. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 163 Topics: Animals; Corpus Luteum; Dehydroepiandrosterone; Disease Models, Animal; Estradiol; Female; Gene Expr	2016
Steroidogenic enzymes of adipose tissue in modulation of trivalent chromium in a mouse model of PCOS. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2017, Volume: 33, Issue:1 Topics: 17-Hydroxysteroid Dehydrogenases; Adipose Tissue; Animals; Aromatase; Chromium; Dehydroepiandrostero	2017
The inhibitory effect of dehydroepiandrosterone and its derivatives against influenza A virus in vitro and in vivo. Archives of virology, 2016, Volume: 161, Issue:11 Topics: Animals; Antiviral Agents; Dehydroepiandrosterone; Disease Models, Animal; Dogs; Humans; Influenza A	2016
Depression-Like Behavior in a Dehydroepiandrosterone-Induced Mouse Model of Polycystic Ovary Syndrome. Biology of reproduction, 2016, Volume: 95, Issue:4 Topics: Animals; Behavior, Animal; Biogenic Monoamines; Brain; Dehydroepiandrosterone; Depression; Diet, Hig	2016
RHOG-DOCK1-RAC1 Signaling Axis Is Perturbed in DHEA-Induced Polycystic Ovary in Rat Model. Reproductive sciences (Thousand Oaks, Calif.), 2017, Volume: 24, Issue:5 Topics: Animals; Cell Line; Dehydroepiandrosterone; Disease Models, Animal; Estrous Cycle; Female; GTP Phosp	2017
Dehydroepiandrosterone in systemic lupus erythematosus. Current rheumatology reports, 2008, Volume: 10, Issue:4 Topics: Adjuvants, Immunologic; Adult; Animals; Cytokines; Dehydroepiandrosterone; Disease Models, Animal; F	2008
Genomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout. Environmental health perspectives, 2008, Volume: 116, Issue:8 Topics: Aflatoxin B1; Animals; Caprylates; Carcinogenicity Tests; Clofibrate; Cluster Analysis; Dehydroepian	2008
Dehydroepiandrosterone (DHEA) prevents the prostanoid imbalance in mesenteric bed of fructose-induced hypertensive rats. European journal of nutrition, 2008, Volume: 47, Issue:7 Topics: Administration, Oral; Animals; Blood Pressure; Dehydroepiandrosterone; Disease Models, Animal; Fruct	2008
Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats. Journal of neuroimmunology, 2009, Feb-15, Volume: 207, Issue:1-2 Topics: Adjuvants, Immunologic; Analysis of Variance; Animals; Cattle; Cell Proliferation; Dehydroepiandrost	2009
An orally bioavailable synthetic analog of an active dehydroepiandrosterone metabolite reduces established disease in rodent models of rheumatoid arthritis. The Journal of pharmacology and experimental therapeutics, 2009, Volume: 329, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Antibodies; Antibody Formation; Arthritis, Rheumatoid; Collagen;	2009
DHEA-dependent and organ-specific regulation of TNF-alpha mRNA expression in a murine polymicrobial sepsis and trauma model. Critical care (London, England), 2009, Volume: 13, Issue:4 Topics: Animals; Base Sequence; Dehydroepiandrosterone; Disease Models, Animal; DNA Primers; Femoral Fractur	2009
Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation, 2009, Sep-29, Volume: 120, Issue:13 Topics: Adjuvants, Immunologic; Angioplasty, Balloon; Animals; Apoptosis; Calcium; Carotid Arteries; Carotid	2009
Demethylation of LHR in dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome. Molecular human reproduction, 2010, Volume: 16, Issue:4 Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; DNA Methylation; Female; Mice; Polycystic O	2010
[Effect of dehydroepiandrosterone on affected and unaffected hindlimb muscles in rats with neuropathic pain induced by unilateral peripheral nerve injury]. Journal of Korean Academy of Nursing, 2009, Volume: 39, Issue:5 Topics: Animals; Body Weight; Dehydroepiandrosterone; Disease Models, Animal; Eating; Hindlimb; Male; Muscle	2009
Depression-like behavior and reduced plasma testosterone levels in the senescence-accelerated mouse. Behavioural brain research, 2010, May-01, Volume: 209, Issue:1 Topics: Acoustic Stimulation; Aging; Analysis of Variance; Animals; Behavior, Animal; Dehydroepiandrosterone	2010
Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis. International journal of molecular medicine, 2010, Volume: 25, Issue:4 Topics: Administration, Oral; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Body Weight; Dehydroe	2010
Activity of lymphocyte subpopulations in polymicrobial sepsis and DHEA treatment in IL-6 knockout mice. Journal of innate immunity, 2010, Volume: 2, Issue:5 Topics: Adjuvants, Immunologic; Animals; CD8-Positive T-Lymphocytes; Dehydroepiandrosterone; Disease Models,	2010
Antiepileptic action of exogenous dehydroepiandrosterone in iron-induced epilepsy in rat brain. Epilepsy & behavior : E&B, 2010, Volume: 19, Issue:3 Topics: Analysis of Variance; Animals; Anticonvulsants; Brain; Dehydroepiandrosterone; Disease Models, Anima	2010
Dehydroepiandrosterone ameliorates hepatocellular damage in obstructive jaundice. Cell biochemistry and function, 2010, Volume: 28, Issue:6 Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Bilirubin; Dehydroepiandrosterone; Disea	2010
Dehydroepiandrosterone modulates survival and immune functions during sepsis depending on the way of drug administration. Medicinal chemistry (Shariqah (United Arab Emirates)), 2010, Volume: 6, Issue:4 Topics: Animals; Apoptosis; Cell Proliferation; Cytokines; Dehydroepiandrosterone; Disease Models, Animal; D	2010
Increased total scavenger capacity and decreased liver fat content in rats fed dehydroepiandrosterone and its sulphate on a high-fat diet. Gerontology, 2011, Volume: 57, Issue:4 Topics: Administration, Oral; Animals; Antioxidants; Catalase; Dehydroepiandrosterone; Dehydroepiandrosteron	2011
Effect of dehydroepiandrosterone on aggrecanase expression in articular cartilage in a rabbit model of osteoarthritis. Molecular biology reports, 2011, Volume: 38, Issue:5 Topics: Adjuvants, Immunologic; Animals; Anterior Cruciate Ligament; Cartilage, Articular; Dehydroepiandrost	2011
Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice, 5XFAD. The International journal of neuroscience, 2011, Volume: 121, Issue:4 Topics: Alzheimer Disease; Animals; Axons; Cell Count; Cells, Cultured; Cerebral Cortex; Dehydroepiandroster	2011
Link between metformin and the peroxisome proliferator-activated receptor γ pathway in the uterine tissue of hyperandrogenized prepubertal mice. Fertility and sterility, 2011, Jun-30, Volume: 95, Issue:8 Topics: Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Dehydroepiandrosterone; Disease	2011
The effect of DHEA treatment on the oxidative stress and myocardial fibrosis induced by Keshan disease pathogenic factors. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2011, Volume: 25, Issue:3 Topics: Animals; Body Weight; Cardiomyopathies; Connective Tissue Growth Factor; Dehydroepiandrosterone; Dis	2011
Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. American journal of physiology. Heart and circulatory physiology, 2011, Volume: 301, Issue:5 Topics: Adult; Animals; Antihypertensive Agents; Apoptosis; Blotting, Western; Bone Morphogenetic Protein Re	2011
Systemic inflammation, cellular influx and up-regulation of ovarian VCAM-1 expression in a mouse model of polycystic ovary syndrome (PCOS). Journal of reproductive immunology, 2011, Volume: 92, Issue:1-2 Topics: Animals; CD4-Positive T-Lymphocytes; Cell Movement; Cells, Cultured; Cytokines; Dehydroepiandrostero	2011
Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer's disease. Acta biochimica Polonica, 2011, Volume: 58, Issue:4 Topics: Acetylcholine; Acetylcholinesterase; Aluminum Chloride; Aluminum Compounds; Alzheimer Disease; Anima	2011
Neurosteroid PREGS protects neurite growth and survival of newborn neurons in the hippocampal dentate gyrus of APPswe/PS1dE9 mice. Current Alzheimer research, 2012, Volume: 9, Issue:3 Topics: Alzheimer Disease; Animals; Animals, Newborn; Dehydroepiandrosterone; Dentate Gyrus; Disease Models,	2012
Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 2012, Volume: 13, Issue:3 Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Dehydroepiandrosterone; Disea	2012
Dehydroepiandrosterone reverses chronic hypoxia/reoxygenation-induced right ventricular dysfunction in rats. The European respiratory journal, 2012, Volume: 40, Issue:6 Topics: Animals; Apoptosis; CREB-Binding Protein; Dehydroepiandrosterone; Disease Models, Animal; Echocardio	2012
Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome. Endocrinology, 2012, Volume: 153, Issue:7 Topics: Adjuvants, Immunologic; Angiopoietins; Animals; Dehydroepiandrosterone; Disease Models, Animal; Endo	2012
A novel compound, denosomin, ameliorates spinal cord injury via axonal growth associated with astrocyte-secreted vimentin. British journal of pharmacology, 2013, Volume: 168, Issue:4 Topics: Animals; Astrocytes; Axons; Cicatrix; Dehydroepiandrosterone; Disease Models, Animal; Male; Mice; Mi	2013
Fine map of the Gct1 spontaneous ovarian granulosa cell tumor locus. Mammalian genome : official journal of the International Mammalian Genome Society, 2013, Volume: 24, Issue:1-2 Topics: Alleles; Androgens; Animals; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Transform	2013
Dehydroepiandrosterone (DHEA) modulates the activity and the expression of lymphocyte subpopulations induced by cecal ligation and puncture. Shock (Augusta, Ga.), 2002, Volume: 18, Issue:5 Topics: Adjuvants, Immunologic; Animals; CD8-Positive T-Lymphocytes; Dehydroepiandrosterone; Disease Models,	2002
[Studies on the anti-tumorpromotion activities of dehydroepiandrosterone and its mechanism of action]. Yao xue xue bao = Acta pharmaceutica Sinica, 2001, Volume: 36, Issue:8 Topics: Animals; Anticarcinogenic Agents; Calcium; Croton Oil; Dehydroepiandrosterone; Disease Models, Anima	2001
Pharmacological characterisation of cortical gamma-aminobutyric acid type A (GABAA) receptors in two Wistar rat lines selectively bred for high and low anxiety-related behaviour. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2000, Volume: 1, Issue:3 Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Binding, Competitive; Cerebral Cor	2000
Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis. Gut, 2003, Volume: 52, Issue:9 Topics: 1-Naphthylisothiocyanate; Animals; Cholangitis, Sclerosing; Chronic Disease; Corticosterone; Dehydro	2003
Enhanced antidepressant efficacy of sigma1 receptor agonists in rats after chronic intracerebroventricular infusion of beta-amyloid-(1-40) protein. European journal of pharmacology, 2004, Feb-20, Volume: 486, Issue:2 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents; Brain; Cinnamates; Conditi	2004
[Effect of dehydroepiandrosterone on Ca(2+)-activated K+ channel of pulmonary arterial smooth muscle cells in pulmonary hypertensive rats]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2004, Volume: 27, Issue:1 Topics: Adjuvants, Immunologic; Animals; Cell Hypoxia; Dehydroepiandrosterone; Disease Models, Animal; Hyper	2004
Protection against inflammatory neurodegeneration and glial cell death by 7beta-hydroxy epiandrosterone, a novel neurosteroid. Neurobiology of disease, 2004, Volume: 15, Issue:2 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aziridines; Cell Death; Choline; Choline O-Acetyl	2004
A novel therapy for acute hepatitis utilizing dehydroepiandrosterone in the murine model of hepatitis. Biochemical pharmacology, 2004, Dec-01, Volume: 68, Issue:11 Topics: Animals; Apoptosis; Chemical and Drug Induced Liver Injury; Concanavalin A; Dehydroepiandrosterone;	2004
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats. Gynecologic and obstetric investigation, 2006, Volume: 61, Issue:4 Topics: 17-Hydroxysteroid Dehydrogenases; Adjuvants, Immunologic; Animals; Chromans; Dehydroepiandrosterone;	2006
Estradiol, but not dehydroepiandrosterone, decreases parasitemia and increases the incidence of cerebral malaria and the mortality in plasmodium berghei ANKA-infected CBA mice. Neuroimmunomodulation, 2006, Volume: 13, Issue:1 Topics: Animals; Brain; Causality; Dehydroepiandrosterone; Disease Models, Animal; Estradiol; Female; Immuni	2006
Altered expression of Fas/Fas ligand/caspase 8 and membrane type 1-matrix metalloproteinase in atretic follicles within dehydroepiandrosterone-induced polycystic ovaries in rats. Apoptosis : an international journal on programmed cell death, 2006, Volume: 11, Issue:9 Topics: Animals; Apoptosis; Caspase 8; Dehydroepiandrosterone; Disease Models, Animal; Fas Ligand Protein; f	2006
Dehydroepiandrosterone alleviates copulatory disorder induced by social stress in male rats. The journal of sexual medicine, 2006, Volume: 3, Issue:4 Topics: Animals; Copulation; Dehydroepiandrosterone; Disease Models, Animal; Ejaculation; Rats; Rats, Spragu	2006
Effect of dehydroepiandrosterone on cartilage and synovium of knee joints with osteoarthritis in rabbits. Rheumatology international, 2006, Volume: 27, Issue:1 Topics: Animals; Anterior Cruciate Ligament; Cartilage; Dehydroepiandrosterone; Disease Models, Animal; Dose	2006
The protective effect of frontal cortex dehydroepiandrosterone in anxiety and depressive models in mice. Pharmacology, biochemistry, and behavior, 2006, Volume: 85, Issue:2 Topics: Animals; Anxiety; Castration; Dehydroepiandrosterone; Depression; Disease Models, Animal; Estradiol;	2006
Effect of DHEA on the hemodynamic response to resuscitation in a porcine model of hemorrhagic shock. The Journal of trauma, 2006, Volume: 61, Issue:6 Topics: Adjuvants, Immunologic; Animals; Blood Pressure; Cardiac Output; Dehydroepiandrosterone; Disease Mod	2006
Hormonal and immunological changes in mice after spinal cord injury. Journal of neurotrauma, 2007, Volume: 24, Issue:2 Topics: Animals; Blood Cell Count; Bone Marrow Cells; Dehydroepiandrosterone; Disease Models, Animal; Human	2007
Evaluation of semi-interpenetrating polymer networks composed of chitosan and poloxamer for wound dressing application. International journal of pharmaceutics, 2007, Aug-16, Volume: 341, Issue:1-2 Topics: Adsorption; Animals; Bandages; Biocompatible Materials; Burns; Cell Survival; Chemistry, Pharmaceuti	2007
Acute effects of neurosteroids in a rodent model of primary paroxysmal dystonia. Hormones and behavior, 2007, Volume: 52, Issue:2 Topics: Animals; Animals, Genetically Modified; Cricetinae; Dehydroepiandrosterone; Desoxycorticosterone; Di	2007
Dehydroepiandrosterone in the nucleus accumbens is associated with early onset of depressive-behavior: a study in an animal model of childhood depression. Neuroscience, 2007, Nov-09, Volume: 149, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Animals; Biogenic Monoamines; Child; Dehydroepiandrost	2007
DHEA lessens depressive-like behavior via GABA-ergic modulation of the mesolimbic system. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:3 Topics: Animals; Antidepressive Agents; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Depression;	2009
The polycystic ovary syndrome and experimental models for the study of its pathogenesis. Progress in clinical and biological research, 1982, Volume: 112 Pt A Topics: Age Factors; Androgens; Animals; Dehydroepiandrosterone; Dihydrotestosterone; Disease Models, Animal	1982
Chemoprevention by dehydroepiandrosterone and indomethacin in a rat multiorgan carcinogenesis model. Cancer research, 1995, Nov-01, Volume: 55, Issue:21 Topics: Animals; Anticarcinogenic Agents; Dehydroepiandrosterone; Disease Models, Animal; Hyperplasia; Indom	1995
Dehydroepiandrosterone reduces progressive dermal ischemia caused by thermal injury. The Journal of surgical research, 1995, Volume: 59, Issue:2 Topics: 17-alpha-Hydroxypregnenolone; Androstenediols; Animals; Back; Burns; Dehydroepiandrosterone; Dihydro	1995
The effect of discontinuing dehydroepiandrosterone supplementation on Zucker rat food intake and hypothalamic neurotransmitters. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1995, Volume: 19, Issue:7 Topics: Androstenedione; Animals; Body Weight; Dehydroepiandrosterone; Disease Models, Animal; Dopamine; Eat	1995
Central effects of dehydroepiandrosterone in Zucker rats. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1995, Volume: 19, Issue:12 Topics: Animals; Biogenic Monoamines; Central Nervous System; Dehydroepiandrosterone; Disease Models, Animal	1995
The polycystic ovarian (PCO) condition: apoptosis and epithelialization of the ovarian antral follicles are aspects of cystogenesis in the dehydroepiandrosterone (DHEA)-treated rat model. Tissue & cell, 1997, Volume: 29, Issue:2 Topics: Androgens; Animals; Apoptosis; Cytoskeleton; Dehydroepiandrosterone; Disease Models, Animal; Epithel	1997
Polycystic ovarian condition in the dehydroepiandrosterone-treated rat model: hyperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles. The Anatomical record, 1997, Volume: 249, Issue:1 Topics: Androstenedione; Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Follicle Stimulati	1997
Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circulation research, 1999, Apr-16, Volume: 84, Issue:7 Topics: Adrenal Glands; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Cholesterol, Dietary; Cholesterol	1999
Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat. European urology, 1999, Volume: 35, Issue:5-6 Topics: Alitretinoin; Animals; Antineoplastic Agents; Dehydroepiandrosterone; Disease Models, Animal; Immuno	1999
Dehydroepiandrosterone-dependent induction of peroxisomal proliferation can be reduced by aspartyl esterification without attenuation of inhibitory bone loss in ovariectomy animal model. Journal of Korean medical science, 2000, Volume: 15, Issue:5 Topics: Acyl-CoA Dehydrogenase; Adjuvants, Immunologic; Animals; Aspartic Acid; Biomarkers; Calcium; Cholest	2000
Dehydroepiandrosterone (DHEA) reduces neuronal injury in a rat model of global cerebral ischemia. Brain research, 2001, Jan-12, Volume: 888, Issue:2 Topics: Animals; Brain Ischemia; Dehydroepiandrosterone; Disease Models, Animal; Dose-Response Relationship,	2001
Chemopreventive efficacy of promising farnesyltransferase inhibitors. Experimental lung research, 2000, Volume: 26, Issue:8 Topics: 3T3 Cells; Adenoma; Alkyl and Aryl Transferases; Animals; Apoptosis; Chemoprevention; Dehydroepiandr	2000
Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Critical care medicine, 2001, Volume: 29, Issue:2 Topics: Adjuvants, Immunologic; Animals; Bacterial Infections; Dehydroepiandrosterone; Disease Models, Anima	2001
Dehydroepiandrosterone attenuates the spontaneous elevation of serum IgE level in NC/Nga mice. Immunology letters, 2001, Dec-03, Volume: 79, Issue:3 Topics: Animals; Cell Differentiation; Dehydroepiandrosterone; Dermatitis, Atopic; Disease Models, Animal; I	2001
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer research, 2001, Oct-15, Volume: 61, Issue:20 Topics: Animals; Anticarcinogenic Agents; Antigens, Polyomavirus Transforming; Apoptosis; Cell Division; Deh	2001
The effects of ACTH and adrenocorticosteroids on seizure susceptibility in 15-day-old male rats. Experimental neurology, 2002, Volume: 175, Issue:1 Topics: Adrenocorticotropic Hormone; Aldosterone; Animals; Corticosterone; Dehydroepiandrosterone; Desoxycor	2002
[Anti-mutagenicity activity of dehydroepiandrosterone]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2002, Volume: 24, Issue:2 Topics: 9,10-Dimethyl-1,2-benzanthracene; Adjuvants, Immunologic; Animals; Antimutagenic Agents; Dehydroepia	2002
Effects of G-6-PD deficiency, experimentally induced or genetically transmitted, on the sorbitol pathway activity. In vitro and in vivo studies. Archives of medical research, 1992,Spring, Volume: 23, Issue:1 Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Aldehyde Reductase; Animals; Black People	1992
Comparison of dehydroepiandrosterone and clofibric acid treatments in obese Zucker rats. The Journal of nutrition, 1989, Volume: 119, Issue:3 Topics: Animals; Blood Glucose; Body Weight; Clofibrate; Clofibric Acid; Dehydroepiandrosterone; Disease Mod	1989
[The effect of nalidixic acid on the course of experimental pyelonephritis under the influence of resistance-affecting drugs]. Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. 1. Abt. Medizinisch-hygienische Bakteriologie, Virusforschung und Parasitologie. Originale, 1970, Volume: 212, Issue:2 Topics: Animals; Antibodies; Antibody Formation; Chemical Phenomena; Chemistry; Dehydroepiandrosterone; Dise	1970
Testicular tumors in the androgen insensitive pseudohermaphrodite rat: histochemistry and steroid metabolism. Gynecologic investigation, 1970, Volume: 1, Issue:3 Topics: Animals; Carbon Isotopes; Chromatography, Thin Layer; Dehydroepiandrosterone; Disease Models, Animal	1970

Intervention	ng/g (Mean)
	DHT concentrations	Testosterone Concentrations
DHT Gel	3.1	0.4
Placebo DHT Gel	2.8	0.6